• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助放化疗与辅助术后放化疗治疗 III 期直肠癌的短期疗效和长期肿瘤学结局:一项病例匹配研究。

Short-term results and long-term oncologic outcomes between neoadjuvant chemoradiotherapy and adjuvant postoperative chemoradiotherapy for stage III rectal cancer: a case-matched study.

机构信息

Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Ann Surg Oncol. 2012 Aug;19(8):2494-9. doi: 10.1245/s10434-012-2311-9. Epub 2012 Apr 5.

DOI:10.1245/s10434-012-2311-9
PMID:22476817
Abstract

PURPOSE

To compare the short-term perioperative results and long-term oncologic outcomes between patients who underwent neoadjuvant chemoradiotherapy (NCRT) and patients who underwent postoperative adjuvant chemoradiotherapy (ACRT) for stage III rectal cancer.

METHODS

From January 1997 to December 2008, a total of 47 patients who were diagnosed as clinical stage III rectal cancer followed by NCRT were matched according to age, gender, and operation method to 47 patients with pathologic stage III rectal cancer who underwent ACRT. Clinical characteristics, surgical and pathologic outcomes, postoperative complications and recovery, and oncologic outcomes were compared between the two groups.

RESULTS

There were no significant differences in demographics or preoperative characteristics between the NCRT and ACRT groups. Though more protective ileostomies were performed in the NCRT group, there was no statistical difference in operation times between the two groups. Patients in the NCRT group had a smaller tumor size (P < 0.001) and a smaller number of lymph nodes retrieved (P < 0.001). No differences were observed with respect to morbidity and recovery outcomes between the two groups. During the median 58-month follow-up periods, the NCRT group showed better disease-free survival and overall survival than the ACRT group (P = 0.002, P = 0.001, respectively).

CONCLUSIONS

NCRT in comparison to ACRT did not increase the risk of postoperative morbidity and provided better disease-free and overall survival in stage III rectal cancer patients.

摘要

目的

比较接受新辅助放化疗(NCRT)和接受术后辅助放化疗(ACRT)的 III 期直肠癌患者的短期围手术期结果和长期肿瘤学结果。

方法

1997 年 1 月至 2008 年 12 月,共 47 例临床诊断为 III 期直肠癌的患者接受 NCRT 治疗,根据年龄、性别和手术方式与 47 例接受 ACRT 的病理 III 期直肠癌患者进行匹配。比较两组患者的临床特征、手术和病理结果、术后并发症和恢复情况以及肿瘤学结果。

结果

NCRT 和 ACRT 组在人口统计学或术前特征方面无显著差异。尽管 NCRT 组行保护性回肠造口术较多,但两组手术时间无统计学差异。NCRT 组肿瘤体积较小(P<0.001)和淋巴结检出数较少(P<0.001)。两组患者的发病率和恢复结果无差异。在中位 58 个月的随访期间,NCRT 组的无病生存率和总生存率均优于 ACRT 组(P=0.002,P=0.001)。

结论

与 ACRT 相比,NCRT 并未增加术后发病率,并为 III 期直肠癌患者提供了更好的无病生存率和总生存率。

相似文献

1
Short-term results and long-term oncologic outcomes between neoadjuvant chemoradiotherapy and adjuvant postoperative chemoradiotherapy for stage III rectal cancer: a case-matched study.新辅助放化疗与辅助术后放化疗治疗 III 期直肠癌的短期疗效和长期肿瘤学结局:一项病例匹配研究。
Ann Surg Oncol. 2012 Aug;19(8):2494-9. doi: 10.1245/s10434-012-2311-9. Epub 2012 Apr 5.
2
Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study.新辅助放化疗对临床怀疑侧方淋巴结受累的中/低位直肠癌患者行侧方盆腔淋巴结清扫术的指征有影响:一项多中心回顾性队列研究。
Ann Surg Oncol. 2014 Jul;21(7):2280-7. doi: 10.1245/s10434-014-3559-z. Epub 2014 Mar 7.
3
Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.与新辅助长疗程放化疗相比,术前序贯短疗程放疗联合FOLFOX化疗改善直肠癌患者的转移和无病生存率:配对分析结果
Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):417-426. doi: 10.1016/j.ijrobp.2017.05.048. Epub 2017 Jun 6.
4
Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence.直肠癌的联合治疗模式:治疗后与治疗前 CEA 作为疾病复发的预后标志物的相对价值。
Ann Surg Oncol. 2012 Aug;19(8):2471-6. doi: 10.1245/s10434-012-2266-x. Epub 2012 Feb 11.
5
Is adjuvant chemotherapy really needed after curative surgery for rectal cancer patients who are node-negative after neoadjuvant chemoradiotherapy?新辅助放化疗后淋巴结阴性的直肠癌患者根治术后是否需要辅助化疗?
Ann Surg Oncol. 2012 Apr;19(4):1206-12. doi: 10.1245/s10434-011-2044-1. Epub 2011 Sep 21.
6
Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.新辅助放化疗后行肿瘤特异性直肠系膜切除术根治性切除固定性局部晚期直肠癌的肿瘤学结局:放疗后病理降期对局部复发和生存的影响。
Ann Surg. 2006 Dec;244(6):1024-30. doi: 10.1097/01.sla.0000225360.99257.73.
7
Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.在新辅助氟尿嘧啶为基础的放化疗后,Ⅱ/Ⅲ期直肠癌中淋巴结状态和TS基因表达是预后标志物。
J Clin Oncol. 2006 Sep 1;24(25):4062-8. doi: 10.1200/JCO.2005.04.2739.
8
Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think!新辅助放化疗后全直肠系膜切除术后标本中少于 12 个淋巴结:这比你想象的要多!
Ann Surg Oncol. 2013 Oct;20(11):3398-406. doi: 10.1245/s10434-013-3010-x. Epub 2013 Jun 30.
9
Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome.新辅助放化疗与 TME 之间间隔时间对局部进展期直肠癌病理反应和肿瘤学结局的影响。
Ann Surg Oncol. 2012 Sep;19(9):2833-41. doi: 10.1245/s10434-012-2327-1. Epub 2012 Mar 27.
10
Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up.随机临床试验术后辅助治疗 II 期和 III 期直肠癌,以确定化疗和放疗的最佳顺序:10 年随访。
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1025-31. doi: 10.1016/j.ijrobp.2010.07.012. Epub 2010 Oct 6.

引用本文的文献

1
Long-Term Survival Analysis of Neoadjuvant Chemoradiotherapy Versus Adjuvant Chemoradiotherapy for Locally Advanced Low Rectal Cancer.新辅助放化疗与辅助放化疗治疗局部晚期低位直肠癌的长期生存分析
Cancer Med. 2025 Aug;14(15):e71042. doi: 10.1002/cam4.71042.
2
Clinical significance of neoadjuvant chemotherapy for locally advanced colorectal cancer patients with deficient mismatch repair: possibly residual value in the era of immunotherapy.错配修复缺陷的局部晚期结直肠癌患者新辅助化疗的临床意义:在免疫治疗时代可能的剩余价值
Therap Adv Gastroenterol. 2023 Jan 19;16:17562848221150306. doi: 10.1177/17562848221150306. eCollection 2023.
3
Effects of Neoadjuvant Radiotherapy on Postoperative Complications in Rectal Cancer: A Meta-Analysis.
新辅助放疗对直肠癌术后并发症的影响:一项Meta分析
J Oncol. 2022 Jan 5;2022:8197701. doi: 10.1155/2022/8197701. eCollection 2022.